These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16730138)

  • 1. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
    Singh AK; Ménard C; Guion P; Simone NL; Smith S; Crouse NS; Godette DJ; Cooley-Zgela T; Sciuto LC; Coleman J; Pinto P; Albert PS; Camphausen K; Coleman CN
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1008-13. PubMed ID: 16730138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
    Simone NL; Ménard C; Soule BP; Albert PS; Guion P; Smith S; Godette D; Crouse NS; Sciuto LC; Cooley-Zgela T; Camphausen K; Coleman CN; Singh AK
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):90-5. PubMed ID: 17855015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
    Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
    Ben-Josef E; Han S; Tobi M; Vargas BJ; Stamos B; Kelly L; Biggar S; Kaplan I
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):81-5. PubMed ID: 11917290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
    Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
    Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study.
    Sanguineti G; Franzone P; Marcenaro M; Foppiano F; Vitale V
    Strahlenther Onkol; 2003 Jul; 179(7):464-70. PubMed ID: 12835883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
    Ben-Josef E; Han S; Tobi M; Shaw LM; Bonner HS; Vargas BJ; Prokop S; Stamos B; Kelly L; Biggar S; Kaplan I
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1160-4. PubMed ID: 12128116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
    Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
    Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we decrease the acute proctitis in prostate cancer patients using hyaluronic acid during radiation therapy: a prospective historically controlled clinical study.
    Stefanelli A; Pascale G; Rainieri E; Ursino S; Colella M; Zini G; Berretta M; Fiorica F
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):639-45. PubMed ID: 22774405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer.
    Hille A; Schmidberger H; Hermann RM; Christiansen H; Saile B; Pradier O; Hess CF
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1488-93. PubMed ID: 16137837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study.
    Maggio A; Magli A; Rancati T; Fiorino C; Valvo F; Fellin G; Ricardi U; Munoz F; Cosentino D; Cazzaniga LF; Valdagni R; Vavassori V
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):518-24. PubMed ID: 24803033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
    Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
    Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.
    Dearnaley DP; Khoo VS; Norman AR; Meyer L; Nahum A; Tait D; Yarnold J; Horwich A
    Lancet; 1999 Jan; 353(9149):267-72. PubMed ID: 9929018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
    Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
    Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis.
    O'Brien PC; Franklin CI; Dear KB; Hamilton CC; Poulsen M; Joseph DJ; Spry N; Denham JW
    Radiother Oncol; 1997 Nov; 45(2):117-23. PubMed ID: 9424000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
    Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
    Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.